πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11904052

Methods for ameliorating infusion reactions

ARBUTUS BIOPHARMA CORPORATION Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904025

Cyclophanes for live-cell imaging

Northwestern University Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904020

Bicyclic peptide ligands specific for TREM2

BicycleTx Limited Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904017

Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904010

Recombinant virus capable of stably expressing target proteins

BOEHRINGER INGELHEIM VETMEDICA (CHINA) CO., LTD. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904028

Security mechanisms for radiopharmaceutical elution system and elution process

Jubilant Draximage Inc. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903994

Dosing regimens

Apellis Pharmaceuticals, Inc. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903993

Ready-to-use bivalirudin compositions

MAIA PHARMACEUTICALS, INC. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903970

Device and methods for platelet lysis or activation

Regenexx, LLC Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903967

Method of preparing T cells with increased activity

AUTOLUS LIMITED Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903952

Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infe

The Regents of the University of Colorado Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903945

Methods of treating antipsychotic-induced weight gain with miricorilant

Corcept Therapeutics Incorporated Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903936

Anti-malarial agents

The Board of Regents of the University of Texas System Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903930

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903922

Compositions and methods for improving mitochondrial function and treating neurodegenerati

Amazentis SA Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903920

Cannabinoid formulation: production method and use

CHIROSYN DISCOVERY TECHNOLOGIES INC. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903966

Intracellular genomic transplant and methods of therapy

Regents of the University of Minnesota Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903973

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904006

Poly(diaminosulfide) particle-based vaccine

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904007

Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904015

Vaccine compositions and methods of use

PDS Biotechnology Corporation Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11904046

Hydrocortisone oral liquid formulations

Eton Pharmaceuticals, Inc. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11905297

OX2R compounds

The Board of Regents of the University of Texas System Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11898207

Methods of isolating neoantigen-specific T cell receptor sequences

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted